No Data
No Data
CervoMed to Participate in Upcoming Investor Conferences
CervoMed Featured in Fortune for Advances in the Treatment of Dementia With Lewy Bodies
Insiders the Biggest Winners as CervoMed Inc.'s (NASDAQ:CRVO) Market Cap Rises to US$151m
CCORF Maintains CervoMed(CRVO.US) With Buy Rating, Maintains Target Price $65
CervoMed Updates Investors on Business and Clinical Progress
Morgan Stanley Maintains CervoMed(CRVO.US) With Buy Rating, Maintains Target Price $35
No Data
No Data
I Am 102927471 :